| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.1 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.078 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |